This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (6) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Zhang, W. Articles by Davidson, J. R. T. Search for Related Content PubMed PubMed Citation Articles by Zhang, W. Articles by Davidson, J. R. T. Social Bookmarking                         What's this?

Levetiracetam in social phobia: a placebo controlled pilot study

Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA, wei.zhang{at}duke.edu

Kathryn M. Connor, MD

Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA

Jonathan R. T. Davidson, MD

Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA

While serotonergic antidepressants are now established as first-line pharamcotherapy for generalized social anxiety disorder (SAD), other agents with different mechanisms have shown promise in treating SAD. The aim of this pilot study is to examine the efficacy and safety of levetiracetam (LEV), an anticonvulsant with calcium channel modulating properties, in treating SAD. Adult outpatients meeting DSM-IV criteria for SAD were randomly assigned (2:1) to double-blind treatment with either LEV (500-3000mg/day) or placebo (PBO) for 7 weeks. The primary outcome measures were the change from baseline in the Brief Social Phobia Scale (BSPS) and response using the Clinical Global Impression of Improvement scale (CGI-I). The mean (SD) BSPS scores at baseline and endpoint were 45.4 (9.7) and 31.2 (19.7) for LEV (n 9), compared to 43.5 (8.4) and 37.8 (19.9) for PBO (n 7) (ITT; ns). Rates of response were 22% for LEV and 14% for PBO using the CGI-I. Using a BSPS response criterion (>30% reduction), response rates were 44% for LEV and 14% for PBO. The effect sizes of LEV relative to PBO were 0.33 for the BSPS and 0.50 for the LSAS. In summary, the results of this study, while negative on the pre-defined measures, suggest promise for LEV as a new treatment of SAD. Further work should be carried out with larger sample sizes and optimal dosing strategies of the drug.

Key Words: levetiracetam • anticonvulsant • calcium-channel • social anxiety disorder

Journal of Psychopharmacology, Vol. 19, No. 5, 551-553 (2005)
DOI: 10.1177/0269881105056526


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Davidson, W. Zhang, K. Connor, J. Ji, K. Jobson, Y. Lecrubier, A. McFarlane, D. Newport, D. Nutt, D. Osser, et al. Review: A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD) J Psychopharmacol, January 1, 2010; 24(1): 3 - 26. [Abstract] [PDF]

				H. Delong and M. H. Pollack Update on the Assessment, Diagnosis, and Treatment of Individuals with Social Anxiety Disorder Focus, October 1, 2008; 6(4): 431 - 437. [Abstract] [Full Text] [PDF]